A Study to Evaluate the Efficacy and Safety of CBL-514 in Participants With Dercum's Disease Lipomas

NCT05387733 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

12

Enrollment

INDUSTRY

Sponsor class

Conditions

Dercum's Disease

Interventions

DRUG: 10 mg CBL-514 per injection
DRUG: 15 mg CBL-514 per injection

Sponsor

Caliway Biopharmaceuticals Co., Ltd.